

**Quality Committee Chair’s Highlight Report to the Trust Board of Directors**

<b>Subject:</b>	Quality Committee Highlight Report	<b>Date:</b> 25 <sup>th</sup> March 2024
<b>Prepared By:</b>	Aly Rashid, Non- Executive Director / Quality Committee Chair	
<b>Approved By:</b>	Aly Rashid, Non- Executive Director / Quality Committee Chair	
<b>Presented By:</b>	Aly Rashid, Non- Executive Director / Quality Committee Chair	
<b>Purpose:</b>		
To provide an update to the Trust BOD following the Quality Committee meeting on 25 <sup>th</sup> March 2024.		<b>Assurance</b>   <b>x</b>

<b>Matters of Concern or Key Risks to Escalate</b>	<b>Major Actions Commissioned / Work Underway</b>
<ul style="list-style-type: none"> <li>IPR Timely Care Update – deep dive into diagnostic activity and backlogs - concern raised regarding the tension between profitability of diagnostic investigations where the tariff or ERF (Elective Recovery Fund) regime make them financially unviable and the need to prioritise schemes on clinical risk rather than purely financial viability – assurance given that ERF schemes were considered across the pathways to include both profitable and non-profitable elements</li> </ul>	<ul style="list-style-type: none"> <li>PSIRF Report- A paper is to be bought back to the Quality Committee in respect to PSIRF so the Committee can gain assurance (and therefore in turn the BOD) in a more robust way, given the quick transition to the new PSIRF system.</li> </ul>
<b>Positive Assurances to Provide</b>	<b>Decisions Made (include BAF review outcomes)</b>
<ul style="list-style-type: none"> <li>Positive Assurance was taken from the highlight reports provided for the Patient Safety Committee, NMAHP Committee and Patient Experience Committee.</li> <li>Positive Assurance provided against the Improvement Overview Report.</li> <li>Positive Assurance taken from the progress made in relation to the Quality Account.</li> </ul>	<ul style="list-style-type: none"> <li>The Committee APPROVED the final version of the Clinical Services Strategy. This will also be provided to the BOD for ratification.</li> <li>The Committee APPROVED the Quality Committee Effectiveness Self-Assessment, further discussion will take place with the Audit and Assurance Committee to consider the impact and value of work underway.</li> <li>The Committee APPROVED the BAF PR1 ,2 and 5, with no changes suggested to the current risk scores in place.</li> </ul>
<b>Comments on effectiveness of the meeting</b>	
Positive level of debate and discussions surrounding the work underway. In particular the focus on outcomes as a measure of success.	
<b>Items recommended for consideration by other Committees</b>	
Committee Effectiveness Self-Assessment to be escalated to the Audit and Assurance Committee for further discussion.	